Last reviewed · How we verify
TG-C
TG-C is a gene therapy that delivers TGF-β3 to cartilage tissue to promote cartilage regeneration and repair.
TG-C is a gene therapy that delivers TGF-β3 to cartilage tissue to promote cartilage regeneration and repair. Used for Articular cartilage defects of the knee.
At a glance
| Generic name | TG-C |
|---|---|
| Also known as | TissueGene-C |
| Sponsor | Kolon TissueGene, Inc. |
| Drug class | Gene therapy |
| Target | TGF-β3 (Transforming Growth Factor Beta 3) |
| Modality | Biologic |
| Therapeutic area | Orthopedics / Regenerative Medicine |
| Phase | Phase 3 |
Mechanism of action
TG-C uses an ex vivo gene therapy approach where patient or donor chondrocytes are transfected with a TGF-β3 gene, then implanted into the damaged cartilage defect. The TGF-β3 protein secreted by these modified cells stimulates cartilage matrix synthesis and tissue regeneration. This approach aims to restore functional cartilage in joint defects.
Approved indications
- Articular cartilage defects of the knee
Common side effects
- Injection site pain or swelling
- Joint effusion
- Infection at implant site
Key clinical trials
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL) (PHASE3)
- Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy (PHASE3)
- Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (PHASE3)
- Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) (PHASE2, PHASE3)
- A Study to Determine the Safety and Efficacy of TG-C in Subjects With Kellgren and Lawrence Grade 2 or 3 OA of the Knee (PHASE3)
- Study to Determine the Efficacy and Safety of TG-C in Subjects With Kellgren/Lawrence Grade 2 or 3 OA of the Knee (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TG-C CI brief — competitive landscape report
- TG-C updates RSS · CI watch RSS
- Kolon TissueGene, Inc. portfolio CI